CREON has exceptional coverage

CREON is widely accepted on most national health plans

93 %

of patients with commercial insurance and Medicare Part D have preferred coverage with the lowest branded co-pay2*

94 %

of patients with commercial insurance and Medicare Part D patients have unrestricted coverage with no prior authorization2†

Medicare Part D coverage for more patients than any other PERT2

Commercial insurance Commercial insurance
Medicare Part D Medicare Part D

92% of patients with commercial insurance have preferred coverage with the lowest branded co-pay2

CREON® (pancrelipase) patients with commercial insurance have preferred coverage with the lowest branded co-pay.

Products listed here are not interchangeable. Material differences exist between products. Consult each individual product’s United States Prescribing Information for full details.

99% of patients with Medicare Part D have preferred coverage with the lowest branded co-pay2

CREON® (pancrelipase) patients with Medicare Part D have preferred coverage with the lowest branded co-pay.

Products listed here are not interchangeable. Material differences exist between products. Consult each individual product’s United States Prescribing Information for full details.

CFCareForward Logo.

Use the formulary lookup tool to see which plans in your area provide coverage for CREON.

Search local coverage

*Preferred coverage varies by channel: commercial (92%) and Medicare Part D (99%).
†Unrestricted coverage varies by channel: commercial (92%) and Medicare Part D (99%).

Preferred means CREON is placed on the plan’s preferred formulary. Lowest Branded Co-Pay means CREON is in the formulary tier status designated by the insurer as the lowest branded co-pay in the therapeutic class. No Restriction/Unrestricted implies no step edit, which can be different than requiring a prior authorization.

PERT = pancreatic enzyme replacement therapy.